Hepatology

 
Investigational GPR119 Agonist Shows Dual Hepatoprotective and Glycemic Benefits in MASH Patients
May 07, 2025

EASL 2025. DA-1241 significantly reduced plasma ALT levels, improved systemic inflammatory and fibrosis biomarkers, according to drug developer MetaVia.

Viking Therapeutics Advances 3 Potential Obesity Treatments Based on Promising 2024 Clinical Trial Results
February 06, 2025

A GLP-1/GIP dual agonist in both subcutaneous and oral tablet formulations and a novel dual amylin and calcitonin receptor agonist lead the company's pipeline for antiobesity medications.

Bariatric Surgery Lowers Risk of Liver Complications in Patients with Cirrhosis, Obesity
January 28, 2025

Metabolic surgery reduced major adverse liver outcomes in people with compensated cirrhosis and obesity by 72%, according to new data.

The Liver Meeting 2024: Bausch Health Presents Phase 3 Study Design for Investigational Rifaximin Formulation to Delay OHE
November 19, 2024

The RED-C clinical trial program highlights the promising potential of the rifaximin soluble solid dispersion immediate-release tablets for delaying early HE-related decompensation.

Semaglutide 2.4 mg: Shows Superior Improvement in Liver Fibrosis, MASH Resolution in Pivotal Phase 3 Trial
November 04, 2024

Novo Nordisk announced the topline findings from the pivotal ESSENCE trial and intends to file applications in early 2025 with US and EU regulators.

Monotherapy with Rifaximin vs Lactulose More Effective for Reducing Recurrence of Overt Hepatic Encephalopathy: New Post Hoc Analysis
October 28, 2024

Rifaximin monotherapy may also confer a survival benefit, according to the study, which was awarded ACG Outstanding Research Award in the Liver Category.

Survodutide: Novel GCGR/GLP-1RA Shows Promise in Obesity, MASH Treatment
September 11, 2024

EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.

Tirzepatide Superior to Placebo in MASH Resolution, Fibrosis Improvement: Daily Dose
June 17, 2024

Your daily dose of the clinical news you may have missed.

Tirzepatide Found Superior to Placebo in MASH Resolution, Fibrosis Improvement
June 13, 2024

More than 50% of patients with MASH receiving 1 of 3 doses of tirzepatide achieved MASH resolution without worsening of fibrosis vs placebo, according to data from phase 2 study.

Two Medication Classes Reduce CV, Liver Events in Persons with T2D, MASLD: Daily Dose
June 11, 2024

Your daily dose of the clinical news you may have missed.